Peter Holm

Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden.

AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden.

Part of Svenska Handelsbanken AB, Handelsbanken Markets Norge is a Norwegian company that provides security brokerage services.

US Food & Drug Administration operates agencies to protect health and human services. It protects and promotes public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices, cosmetics, animal foods and feed and veterinary products. The company was founded by Theodore Roosevelt and Harvey Washington Wiley on 30th June, 1906 and is headquartered in Silver Spring, MD.

Sana Pharma Medical AS develops topical analgesic products. It develops products against various chronic pain conditions, including osteoarthritis of the knee. Its product 2PX provides clinical benefit in the management of both nociceptive and neuropathic pain. The company was founded in 2002 and is headquartered in Oslo, Norway.

AnaMar AB develops drugs and provides research services for chronic joint diseases. It focuses on the discovery, development and commercialization of novel therapeutic strategies to treat debilitating inflammation and pain. The company was founded in 1998 and is headquartered in Lund, Sweden.

Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway.

Caerus Capital AS develops a process to produce heparin from marine raw materials. It focuses on developing novel anticoagulant agents based on biomass from the fish farming industry. The firm's technological platform is based on patented processes for extraction and purification of heparin using marine species-specifically salmon intestines-as raw material. The company was founded by Ragnar Flengsrud on December 4, 2001 and is headquartered in Hovik, Norway.

Part of Biotage AB, Biotage Sweden AB is a Swedish impact tech company committed to solving society ’ s problems. The company is based in Uppsala, Sweden. The company offers solutions in drug discovery, analytical, water, and environmental testing. Biotage provides workflow solutions and products to customers in drug discovery and development, analytical testing, and water and environmental testing. The company was founded in 1989 by Sheridan G. Snyder.

Caerus Consulting AS engages in the research and development in biotechnology. It develops antibiotics for life threatening bacterial diseases. Its technological core is chemistry on complex molecules. The company was founded by Torgeir Vaage on March 31, 2009 and is headquartered in Hovik, Norway.

GeneSeque AS provides single-molecule DNA-sequencing technology. It develops MagSeq, a break-through technology for single-molecule sequencing. The company was founded on February 12, 2008 and is headquartered in Trondheim, Norway.

NovaSAID AB develops treatments for inflammation and pain in conditions such as rheumatoid arthritis. It discovers selective microsomal prostaglandin E synthase-1 (mPGES-1), and has also demonstrated its effect in animal models for pain and inflammation. The firm's approach is to prevent the pathological formation of prostaglandin E2 (PGE2) selectively, through the development of inhibitors of mPGES-1, the enzyme that is responsible for the formation of PGE2 during inflammation. Its mPGES-1 inhibition offers an approach for inhibiting pathological PGE2 production without adversely affecting other important prostanoids. The company was founded by Per-Johan Göte Jakobsson, Ralf Morgenstern, Bertil Samuelsson and Bengt Ingemar Samuelsson on October 26, 2004 and is headquartered in Solna, Sweden.

Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark.

Palette Life Sciences AB operates as a pharmaceutical company. It specializes in developing products for local pain relief in obstetrics and gynecology. The company was founded by Berith Karlsson Tingåker, Gunvor Ekman-Ordeberg, Arne Folke Brodin and Lars Irestedt in 2009 and is headquartered in Solna, Sweden.

Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark.

Conrig Pharma ApS provides drug for oral treatment of atopical disease. Its new drug (CRG-010) is use for topical treatment of itch/pruritus associated with atopical dermatitis. The company was founded by John Bondo Hansen and Mikael Sondergaard Thomsen on December 20, 2010 and is headquartered in Copenhagen, Denmark.

Observe Medical International AB develops medical technology products. It produces digital urine meters which measures biofilm build-up. The firm’s product Sippi is an automated digital urine measurement system which detects surface degradation and impending biofilm formation. The company was founded by Per Magnus Emmoth, Mikael Charléz and Mikael Löfgren and is headquartered in Gothenburg, Sweden.

Disruptive Materials AB manufactures mesoporous magnesium carbonate. It focuses on commercializing the material Upsalite that can be used in applications such as desiccant for humidity control, pharmaceutics, adsorbent for waste handling, thermal and acoustic insulation, cosmetics, adsorbent in ink jet paper,and bio material applications. The company was founded by Johan A. V. Gómez de la Torre, Maria Strømme, Lars-Erik Mattias Karls, and Sara Kristina Frykstrand Ångström in December 2011 and is headquartered in Uppsala, Sweden.

Immuneed AB develops drugs. The firm offers as a contract research organization and provides specialized services for immunotoxicology and immunophenotyping. Its services include cytokine release assay, complement activation, cellular drug biodistribution, cell activation patterns, immune recall responses, viability analyses, blood status and mode-of-action studies. The company was founded by Sara Mangsbo, Erika Fletcher and Thomas Totterman in 2014 and is headquartered in Uppsala, Sweden.

NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark.

Haracon AB provides corporate consulting services.

Gesynta Pharma AB develops and manufactures novel oral treatments for patients with chronic inflammatory conditions. The company was founded by Gunilla Anders Ekström, Charlotte Elisabet Edenius, Urban Paulsson, Ralf Morgenstern, Per-Johan Göte Jakobsson and Patric Stenberg in 2017 and is headquartered in Solna, Sweden.

Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark.

STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark.

Disruptive Pharma AB is a pharmaceutical company based in Uppsala, Sweden, with a passion for innovation in drug products. The Swedish company has perfected the groundbreaking mesoporous magnesium carbonate (mmc) drug delivery technology, which makes it easier to develop amorphous drug candidates. By combining the mmc formulation technology with drug compounds, they can enhance existing products or assist in formulating new therapies. Disruptive Pharma seeks commercial partnership or licensing to industry partners within the drug improvement business area. The company was founded in 2018 by Maria Strömme, and the CEO is Peter Åsberg.

Strike Pharma AB is a Swedish company that specializes in developing therapeutic vaccines for solid tumors. The company is based in Uppsala, Sweden and was founded in 2020 by Pierre Dönnes and Sara Mangsbo. The company utilizes ADAC technology to create personalized immunotherapy for their patients. Mårten Winge has been the CEO of the company since 2021.